Figure 3.

Recombinant anticoagulant activated protein C later in the course of experimental cerebral malaria has only mild effects on clinical progression and survival. In order to investigate whether murine anticoagulant activated protein C (mAPC) later in the course of experimental cerebral malaria (ECM) can still influence clinical progression, 2 doses of mAPC were administered on day +3 following Plasmodium berghei innoculation. Once again, (A) clinical progression and (B) overall survival were both mildly improved in mice treated with mAPC compared to controls. Mouse survival data were compared using a log-rank (Mantel-Cox) Test.